Skip to main content

 

 

For your patients with hemophilia A who are looking for a product that’s ready to go, proven effective, and has an established safety profile, Novoeight® offers all three.

Michael, 30 years old, lives with hemophilia A.


Michael,
30 years old, lives with hemophilia A. 

For your patients with hemophilia A who are looking for a product that’s ready to go, proven effective, and has an established safety profile, Novoeight® offers all three.


Novoeight® is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.1 Novoeight® is not indicated for the treatment of von Willebrand disease.


Novoeight® at a glance:

Shield Checkmark icon

Reliable

Effective bleed control, with a median of 1.4 bleeds in the long-term safety trial.1
Read the data

Backpack icon

Portable

To support his busy lifestyle, Novoeight® offers a higher degree of stability—it's the only rFVIII with stability up to 104°F for up to 3 months.1,a    
Learn about portability

Funnel icon

Safety

Proven safety profile, with 0 inhibitors confirmed for PTPs and over 9 years of clinical experience.2,b
See the study results

Umbrella icon

Access

Is he covered? Novo Nordisk is working to improve insurance access for your patients.
Find out about access

rFVIII=recombinant factor VIII.
PTP=previously treated patient.
aCompared with other recombinant FVIII products.3-11
b
guardian™1: a multicenter, multinational, open-label, single-arm efficacy and safety trial in 150 patients (aged 12 to 65 years) with severe hemophilia A on a prophylactic treatment regimen who were exposed to turoctocog alfa for a mean of 85 exposure days (ranging from 11 to 172 exposure days).2

Popular education for your patients.

  See All

Do your patients want a portable treatment?

Novoeight® offers stability up to 104˚F for up to 3 months before reconstitution, plus the longest room temperature storage time after reconstitution.1,c It's the storage flexibility they need to help them stay on the go.


cCompared with other recombinant FVIII products.3-11


Peter
lives with hemophilia A.
 

Featured professional education.

  See All

  • Professional Brochure

    This brochure will help you understand how the portability features of Novoeight—with stability up to 104°F for up to 3 months—may be appropriate for your patients with active lifestyles.

  • Now on MedTalks

    Dr. Tarantino sits down with Team Novo8™ member Tammy Davenport to put women with hemophilia in the spotlight. Tune in to hear them discuss the need for better comprehensive care and treatment options for female patients and how they're raising awareness.

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.

References

  1. Novoeight [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2018.
  2. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013; 19:691-697.
  3. Kogenate® [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2016.
  4. Advate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2018.
  5. Eloctate™ [package insert]. Cambridge, MA: Biogen Idec Inc.; 2017.
  6. Adynovate® [package insert]. Westlake Village, CA: Baxalta US Inc., 2018.
  7. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
  8. Xyntha® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2014.
  9. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2017.
  10. Nuwiq® [package insert]. Hoboken, NJ: Octapharma USA, Inc.; 2017.
  11. Kovaltry® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2016.